BUZZ-Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial
Oncolytics Biotech's shares rose 5.7% after the U.S. FDA approved the design for a clinical trial of pelareorep in advanced pancreatic cancer. The trial will compare chemotherapy alone versus chemotherapy plus pelareorep, with an option to add a checkpoint inhibitor. Pelareorep has shown promise in previous studies and has FDA Fast Track status.
U.S.-listed shares of Oncolytics Biotech (ONCY.O) rise 5.7% to $1.09 premarket
Co says it has reached an agreement with the U.S. FDA on the design of a major clinical trial for its experimental cancer drug, pelareorep, in patients with advanced pancreatic cancer
Pancreatic cancer is an aggressive disease with limited treatment options; trial aims to add immunotherapy to standard chemo - ONCY
ONCY says main goal is overall survival
Co says study will compare chemo alone vs. chemo plus pelareorep, with an option to add another type of cancer drug called a checkpoint inhibitor
Pelareorep has shown promise in earlier pancreatic and breast cancer studies; both programs have FDA Fast Track status - ONCY
Up to last close, stock up 13% YTD
